Evenity (Romosozumab) Side Effects: Delayed-Onset and Rare Adverse Events Women Need to Know

What Makes Romosozumab Different From Other Osteoporosis Drugs

Romosozumab works by a mechanism no other approved osteoporosis drug uses. It blocks sclerostin, a protein secreted by osteocytes that normally puts the brakes on new bone formation. Block sclerostin and you get a simultaneous spike in bone formation and a drop in bone resorption. The result is rapid, large gains in bone mineral density, particularly in the lumbar spine.

That dual action is clinically meaningful. In the FRAME trial, 12 months of romosozumab reduced new vertebral fracture risk by 73% compared with placebo in postmenopausal women with osteoporosis. Lumbar spine BMD rose by 13.3% and total hip BMD by 6.9% at 12 months. No bisphosphonate or denosumab achieves those numbers in a single year.

The speed and magnitude of that bone-building effect, though, is exactly what makes the safety profile worth studying closely. Biological pathways that drive rapid tissue remodeling rarely affect only one organ system. Sclerostin is expressed in vascular smooth muscle and cardiac tissue, not just bone. That is the root of the cardiovascular concern and a reason this drug requires closer monitoring than most oral osteoporosis therapies.

Who Gets Romosozumab

The FDA approved romosozumab specifically for postmenopausal women with osteoporosis at high fracture risk, defined as a prior osteoporotic fracture, a T-score at or below minus 2.5 at the spine or hip, or multiple clinical risk factors. The treatment course is fixed at 12 monthly injections. After the final injection, women transition to an antiresorptive drug, typically a bisphosphonate or denosumab, to preserve the gains.

Because the approved population is postmenopausal, almost every real-world safety dataset comes from women in their late fifties through seventies. Extrapolating the risk profile to premenopausal women or to women in perimenopause is not supported by clinical trial data.

The Boxed Warning: Cardiovascular Risk Is Not Theoretical

The FDA added a boxed warning to romosozumab after the ARCH trial showed a higher rate of serious cardiovascular events in women receiving romosozumab compared with those receiving alendronate. In ARCH, 2.5% of the romosozumab group experienced a serious cardiovascular adverse event versus 1.9% in the alendronate group during the 12-month treatment period.

The absolute difference was small but statistically meaningful, and the mechanism is biologically plausible. Sclerostin inhibition in vascular tissue may alter calcification dynamics in arteries. The FRAME trial did not show the same signal, possibly because the comparator in FRAME was placebo rather than an active drug with known cardiovascular-protective effects.

What the Boxed Warning Means for You Clinically

Romosozumab is contraindicated if you have had a myocardial infarction or stroke within the 12 months before your first injection. Your prescribing clinician should take a full cardiovascular history before the first dose and reassess at each monthly visit.

Women with multiple cardiovascular risk factors, including hypertension, current smoking, type 2 diabetes, or established coronary artery disease, need an individualized risk-benefit conversation before starting. The question is not whether you have any risk. The question is whether your fracture risk at this moment outweighs a modest incremental cardiovascular risk over 12 months.

Why This Is a Delayed-Onset Concern

The ARCH cardiovascular signal appeared within the first 12 months of therapy, but individual events can occur at any point during the treatment course, including in the final months. Women who begin treatment without declaring a recent cardiac event are at the highest risk of a late-in-course event going unrecognized as drug-related. Post-market FAERS reports continue to capture cardiovascular events attributed to romosozumab months after therapy started.

Atypical Femur Fractures: A Delayed Signal Shared With Antiresorptives

Atypical femur fractures (AFF) are stress fractures that occur in the subtrochanteric or diaphyseal femur, often with minimal or no trauma. They were first identified with long-term bisphosphonate use. The concern with romosozumab is different in character: the drug's potent antiresorptive component, during the 12-month course, may theoretically contribute to similar microdamage accumulation in some women.

Post-market case reports of AFF during romosozumab therapy have been submitted to regulatory agencies. The FDA prescribing information lists AFF as a potential risk. The absolute rate in women using romosozumab for only 12 months appears lower than in women using bisphosphonates for five or more years, but direct comparative incidence data in large registries are not yet available. Be candid about this evidence gap: most AFF data comes from bisphosphonate cohorts, and the romosozumab-specific rate is extrapolated, not directly measured in prospective studies.

Warning Symptoms You Should Not Ignore

New, dull, aching thigh or groin pain, particularly in the absence of a specific injury, can precede an AFF by weeks to months. Report any such pain to your prescriber immediately. Your clinician may order bilateral femur X-rays or MRI to look for a cortical stress reaction before a complete fracture occurs. ACOG and other societies recommend this proactive imaging approach when AFF symptoms arise during any potent bone-targeted therapy.

Both Femurs Are at Risk

AFF tends to be bilateral. If one femur shows early cortical thickening or a beaking pattern on imaging, the contralateral side should be evaluated at the same time. This is not a theoretical precaution. A case series published in JBMR found bilateral involvement in approximately 28% of AFF cases across antiresorptive drug classes.

Osteonecrosis of the Jaw: Low Incidence, High Impact

Osteonecrosis of the jaw (ONJ) is exposed or necrotic bone in the jaw persisting for more than eight weeks, arising in the absence of radiation or metastatic disease to the jaw. Its incidence with osteoporosis-dose antiresorptive therapy, including bisphosphonates and denosumab, is estimated at roughly 1 in 10,000 to 1 in 100,000 patient-years in the non-oncology setting. Romosozumab carries an ONJ warning in its prescribing information; however, the absolute rate in the 12-month treatment window appears lower than with years of bisphosphonate therapy. Prospective incidence data specific to romosozumab remain limited.

Risk Factors That Matter for Women

Women are not at uniformly equal ONJ risk. The following factors increase it:

• Active dental infection, periodontal disease, or recent tooth extraction
• Concurrent corticosteroid therapy
• Poorly controlled diabetes
• Tobacco use
• Prior or concurrent antiresorptive therapy (bisphosphonates in particular accumulate in bone for years)

The Dental Clearance Requirement

Standard practice, supported by guidelines from AAOMS and reflected in the romosozumab label, is to complete any necessary invasive dental procedures before starting therapy. During the 12-month course, avoid elective tooth extractions where possible. If urgent dental surgery is needed, inform both your prescribing clinician and your dentist that you are on romosozumab.

Hypocalcemia: The Earliest Delayed Effect and the Most Preventable

Romosozumab shifts calcium balance toward bone rapidly. If your calcium and vitamin D intake are inadequate before the first injection, serum calcium can fall within days to weeks. Symptomatic hypocalcemia, including muscle cramps, perioral tingling, and cardiac arrhythmia in severe cases, is a known adverse event listed in the prescribing information.

The FRAME trial excluded women with severe vitamin D deficiency, which is part of why hypocalcemia rates in the trial were low. In real-world practice, women present with a far wider range of baseline vitamin D levels. A 2022 post-market review in Osteoporosis International found that hypocalcemia was among the most common adverse events reported to FAERS in romosozumab users, with onset typically within the first two months.

What You Need Before Your First Injection

Your prescriber should check:

• Serum 25-hydroxyvitamin D (target at or above 30 ng/mL before starting)
• Serum calcium and albumin-corrected calcium
• Kidney function (eGFR), because renal impairment amplifies hypocalcemia risk

Romosozumab supplementation guidance recommends at least 500 mg calcium and 400 IU vitamin D daily throughout the 12-month course, though many women's-health clinicians recommend higher vitamin D targets, particularly in women who are dark-skinned, have limited sun exposure, or have obesity (which reduces vitamin D bioavailability).

Injection-Site Reactions and Early Local Effects

Injection-site reactions are among the most common adverse events in the FRAME and ARCH trials. Approximately 18% of women in ARCH reported an injection-site reaction, compared with 7% in the alendronate group. These reactions typically include pain, redness, and bruising at the site of one or both of the monthly subcutaneous injections. They tend to occur within hours of injection and resolve within a few days.

These are not delayed-onset effects, but women should know they may persist or recur at subsequent monthly visits. Rotating injection sites between the abdomen, upper arm, and thigh can reduce local irritation.

Arthralgia, Headache, and Musculoskeletal Effects

In the FRAME trial, arthralgia was reported in 12.6% of romosozumab recipients versus 11.7% in the placebo group, a modest difference. Headache occurred in about 8% of treated women. These effects generally appeared within the first few months of therapy.

The musculoskeletal aching some women describe is distinct from AFF-related thigh pain. Generalized joint discomfort tends to be diffuse and bilateral, without the localized, weight-bearing quality of an impending stress fracture. Keeping a symptom diary with dates and pain locations helps your clinician distinguish between a routine musculoskeletal effect and a signal worth imaging.

Potential for Rebound Bone Loss After Therapy Ends

This is one of the most clinically important and underappreciated aspects of romosozumab. When the 12-month course ends and sclerostin inhibition is removed, the bone formation rate falls rapidly toward baseline. If no antiresorptive is started afterward, BMD can decline significantly within 12 months. Data from the FRAME open-label extension showed that women who transitioned from romosozumab to denosumab maintained or continued to gain BMD, while those who went untreated lost bone rapidly.

This rebound is not a toxicity in the traditional sense, but a failure-to-maintain outcome with real clinical consequences. If you finish your 12-month Evenity course and your prescriber does not discuss what comes next, ask explicitly about the transition plan. Starting a bisphosphonate or denosumab within 30 to 60 days of the last romosozumab injection is the evidence-based approach.

The three-phase decision framework a WomanRx clinician uses for romosozumab transitions:

Phase 1 (months 1-12): Romosozumab plus calcium and vitamin D, cardiovascular monitoring, and dental clearance before month 1.

Phase 2 (months 12-24): Immediate transition to antiresorptive (denosumab or bisphosphonate) within 30 to 60 days of final injection.

Phase 3 (year 2 onward): Periodic DXA reassessment at 2 years to determine whether continued antiresorptive therapy, a drug holiday, or dose adjustment is appropriate based on T-score, fracture history, and tolerability.

Skipping Phase 2 is the single most common real-world error in romosozumab management and leads to preventable bone loss.

Who This Drug Is Right For and Who It Is Not

Women Most Likely to Benefit

Postmenopausal women who meet at least one of the following criteria are the strongest candidates:

• T-score at or below minus 2.5 at the spine or hip with one or more fragility fractures
• Very high fracture risk as defined by FRAX 10-year probability above thresholds set by NOGG or NOF guidelines
• Failed or inadequately responded to a bisphosphonate after two or more years of therapy
• High vertebral fracture burden requiring rapid BMD gain

Women Who Should Not Receive Romosozumab

• History of myocardial infarction or stroke within the past 12 months (contraindicated by boxed warning)
• Uncorrected hypocalcemia
• Known hypersensitivity to romosozumab
• Pregnancy (see next section)

Women in perimenopause, those who are premenopausal, and those who are still cycling are not in the approved indication. That does not mean their fracture risk is zero, but romosozumab has not been studied in this population and no dosing guidance exists for pre- or perimenopausal fracture management.

Pregnancy, Lactation, and Contraception

This section is required reading if you are of reproductive age or considering conception.

Romosozumab is contraindicated in pregnancy. Sclerostin plays a role in fetal skeletal development, and animal studies using doses comparable to human exposure showed fetal harm including increased post-implantation loss and skeletal abnormalities. There are no adequate human data on romosozumab use during pregnancy. The FDA label assigns romosozumab to the category of drugs where animal data indicate risk and human data are absent.

Because the approved indication is postmenopausal women, pregnancy is generally not expected. However:

• Women who begin menopause early (before age 45) and have uncertainty about their menopausal status should confirm with FSH and estradiol levels before starting.
• Women using assisted reproductive technology or donor eggs near the boundary of menopause need explicit confirmation that conception is not possible before the first injection.
• If a woman on romosozumab discovers she is pregnant, the drug should be stopped immediately and the pregnancy reported to the Amgen pharmacovigilance program (1-800-77-AMGEN).

Lactation: Romosozumab's transfer into human breast milk has not been studied. Given the molecular weight and the potential for harm, breastfeeding during romosozumab therapy is not recommended. Again, the approved postmenopausal population makes lactation rare in practice, but it is not impossible in cases of very early surgical or medical menopause.

Contraception: No specific contraception requirement is listed in the label for women verified to be postmenopausal. For women with any uncertainty about menopausal status, reliable contraception during the 12-month course is a clinically reasonable precaution given the animal reproductive data.

Rare But Reported Adverse Events From Post-Market Surveillance

The FAERS public dashboard and published case reports have identified several adverse events not prominent in phase III trials:

• Hypersensitivity reactions: Rare reports of urticaria, erythema multiforme, and dermatitis. Anaphylaxis has been reported in post-market use. Most reactions occurred within minutes to hours of injection.
• Hypertension: Both FRAME and ARCH noted higher blood pressure in romosozumab arms. Sclerostin inhibition in vascular smooth muscle may affect arterial stiffness; this effect warrants monitoring in women with borderline hypertension before starting.
• New or worsening heart failure: A small number of cases identified through FAERS. The mechanism is unclear but consistent with the broader cardiovascular signal.
• Drug-antibody formation: Approximately 18% of women in FRAME developed binding antibodies to romosozumab, and 4% developed neutralizing antibodies. These did not appear to affect efficacy or safety in the trial data, but long-term implications in real-world use are not fully characterized.

A 2023 pharmacovigilance analysis of FAERS data from romosozumab's approval through 2022 found that cardiovascular events, hypocalcemia, and injection-site reactions accounted for the majority of reported serious adverse events, consistent with the known label-based risk profile.

Monitoring Schedule During and After Romosozumab Therapy

Based on the prescribing information and standard women's-health practice, the following monitoring is appropriate:

| Time Point | What to Check | |---|---| | Before first injection | Serum calcium, 25-OH vitamin D, eGFR, cardiovascular history, dental clearance | | Monthly (each injection visit) | Blood pressure, new cardiac or neurological symptoms, injection-site assessment | | Month 6 | Symptom review for thigh or groin pain, jaw symptoms | | Month 12 (end of course) | DXA at spine and hip, serum calcium, transition planning | | 12-24 months post-therapy | Repeat DXA, fracture surveillance, antiresorptive adherence review |

Women with baseline cardiovascular risk factors may benefit from a cardiology co-consult before month 1, not after a problem has arisen.

What the Evidence Leaves Unanswered

Women are substantially underrepresented in the broader osteoporosis literature for subgroup analyses by race and ethnicity. The FRAME trial enrolled women globally but did not publish subgroup efficacy or safety data by race in sufficient depth to guide individualized risk counseling across all populations. Black women in particular have historically lower rates of DXA screening and were underrepresented in most romosozumab trials, meaning the safety and efficacy data are largely extrapolated from predominantly White and Asian cohorts.

The cardiovascular risk profile in women with pre-existing controlled hypertension or with metabolic syndrome has not been prospectively studied. The ARCH comparator was alendronate, and it is not clear whether the cardiovascular signal would look the same against placebo alone in a population matched for cardiovascular risk.

These are real gaps. Acknowledging them is not a reason to avoid the drug when it is indicated; it is a reason to monitor more carefully and to report adverse events through MedWatch when they occur, because post-market surveillance is how these gaps close.